Related Experiment Videos
CD4 monoclonal antibody administration in atopic dermatitis
E Robinet1, C Stamm, J F Nicolas
1Laboratory of Immunology, Lyon, France.
Journal of the American Academy of Dermatology
|April 1, 1997
Summary
Short-term CD4 monoclonal antibody (mAb) therapy showed potential for treating severe atopic dermatitis (AD). However, careful consideration of Th1/Th2 imbalance is crucial for future treatment protocols.
Area of Science:
- Immunology
- Dermatology
- Clinical Trials
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition linked to dysregulated helper T cell type 2 (Th2) activation.
- Severe AD cases often require treatments like cyclosporine.
Purpose of the Study:
- To evaluate the efficacy of short-term CD4 monoclonal antibody (mAb) therapy in adults with severe AD.
- To assess the safety and clinical impact of CD4 mAb B-F5 in AD patients.
Main Methods:
- Three patients with severe refractory AD received a 2-day infusion of the CD4 mAb B-F5.
- Two patients with severe psoriasis were included as controls to assess the mAb's effects.
Main Results:
- CD4 mAb B-F5 was generally well-tolerated, with manageable side effects.
- Two out of three AD patients showed clinical improvement; one experienced worsening with increased activated immune cells and eosinophilia.
- The CD4 mAb significantly improved psoriasis lesions in the control group.
Conclusions:
- CD4 mAb infusion presents potential therapeutic benefits for AD.
- Future treatment strategies must address the risk of exacerbating the Th1/Th2 imbalance characteristic of AD.